ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1378 National Cancer Institute Html en Childhood Brain Stem Glioma Treatment (PDQ®)–Health Professional Version Diffuse intrinsic pontine glioma (DIPG) is a fast-growing childhood brain stem glioma that is difficult to treat and has a poor prognosis. A focal glioma grows more slowly, is easier to treat, and has a better prognosis. Learn about the diagnosis, cellular classification, staging, treatment, and clinical trials for pediatric brain stem glioma in this expert-reviewed summary.
corresponding treatment summary0.689411
focal brainstem gliomas0.801159
brain stem tumours0.666641
diffuse brainstem gliomas0.915552
adult high-grade gliomas0.779058
brain tumors0.871609
children0.712329
histologic confirmation0.674199
pediatric high-grade gliomas0.777704
diffuse intrinsic brain0.79588
clinical trials0.703298
Tumors Treatment Overview0.783812
H3 K27M mutation0.767013
phase I/II study0.654843
Primary tumors0.67784
high-risk brainstem tumors0.802443
World Health Organization0.800016
brain stem tumors0.783084
single new treatment0.675971
brainstem gliomas0.982733
specific H3 K27M0.672189
common solid tumor0.66912
radiation therapy0.772489
intrinsic pontine glioma0.876111
diffuse pontine gliomas0.849232
Diffuse brainstem glioma0.837788
et al.0.72856
intrinsic brainstem gliomas0.920288
childhood cancer mortality0.676419
intrinsic pontine gliomas0.828567
Glioma Cooperative Group0.697725
brain tumor treatment0.735178
brain stem gliomas0.821857
3-dimensional conformal radiation therapy0.714672
low-grade morphological characteristics0.653573
Pediatr Blood Cancer0.768008
paediatric pontine glioma0.728445
diffuse intrinsic brainstem0.904976
Primary brain tumors0.784905
Abstract0.747074
pediatric brain tumors0.745588
nervous system tumors0.673857
H3 K27M mutation.0.670015
Clin Oncol0.65677
childhood brain tumors0.756852
newly diagnosed diffuse0.79983
pediatric diffuse0.708327
thalamic tumors0.673454
midline high-grade gliomas0.786516
CLICK HERE
1606 National Cancer Institute Html en Esophageal Cancer Screening (PDQ®)–Patient Version Expert-reviewed information summary about tests used to detect or screen for esophageal cancer.
cancer treatment0.387405
ongoing clinical trials0.392728
Esophageal cells0.394141
following PDQ summaries0.45401
PDQ cancer information0.609599
false-negative test result0.383414
cell esophageal cancer0.474658
lower esophageal sphincter0.425437
esophageal cancer screening0.538472
clinical trials0.540395
test result0.424347
cancer information summary0.521921
clinical trial0.401913
risk factors0.432802
breast cancer prevention0.411928
false-positive test result0.383086
cancer patients0.381861
latest published information0.3956
early Barrett esophagus0.54548
NCI’s PDQ0.405873
cancer symptoms0.40272
NCI PDQ cancer0.478991
tests0.414709
esophageal adenocarcinoma0.437047
PDQ Screening0.430577
esophageal cancer0.833194
screening tests0.389343
esophageal cancer increases0.474161
Cancer Information Service0.428795
Prevention Editorial Board0.449486
treatment clinical trials0.391268
fewer new cases0.389051
National Cancer Institute0.535839
PDQ documents0.397318
new treatment0.396213
Cancer screening trials0.467493
Cancer Care page0.416248
PDQ database0.401252
risk factor0.382958
PDQ summary0.423142
cancer information summaries0.436287
health professional versions0.379866
lining0.379758
comprehensive cancer information0.436148
cancer0.985172
esophagus produce0.441607
esophagus0.633278
squamous cell carcinoma0.55263
CLICK HERE
1753 National Cancer Institute Html en Hormone Therapy for Breast Cancer A fact sheet that describes types of hormone therapy, its role in preventing and treating breast cancer, and possible side effects.
Surgical Adjuvant Breast0.492707
estrogen0.502159
primary breast cancer0.489122
early-stage ER-positive breast0.480551
aromatase inhibitors anastrozole0.480936
ER-positive early-stage breast0.480383
aromatase inhibitors0.525562
breast cancer subtypes0.491642
metastatic ER-positive breast0.481109
early-stage breast cancer0.616245
tamoxifen0.550216
breast cancer hormone0.522198
ER-positive breast cancer0.553345
breast cancer prevention0.522495
breast cancer patients0.511592
postmenopausal breast cancer0.509489
new breast cancer0.500245
adjuvant hormone therapy0.504935
estrogen receptors0.483294
HR-positive breast cancer0.521679
hormone receptor-positive breast0.501962
metastatic breast cancer0.52726
invasive breast cancer0.511911
early breast cancer0.587772
breast cancer cells0.575964
breast cancer recurrence0.50934
breast cancers0.514423
ER-positive breast cancers0.488424
premenopausal women0.499525
National Cancer Institute0.500748
IBIS-I breast cancer0.488534
hormone therapy0.718328
hormone-sensitive breast cancer0.587411
breast tumors0.505842
postmenopausal women0.702436
breast cancer risk0.498557
International Breast Cancer0.496186
Letrozole Breast Cancer0.491109
estrogen receptor0.488845
advanced hormone-sensitive breast0.480069
receptor–positive breast cancer0.52072
breast cancer0.988243
Breast Cancer Trialists0.51995
adjuvant tamoxifen0.489054
tamoxifen treatment0.48115
hormone receptor–positive breast0.534822
et al0.566786
advanced breast cancer0.554835
CLICK HERE
1762 National Cancer Institute Html en Access to Investigational Drugs A fact sheet that defines investigational drugs (drugs under study but not yet FDA approved) and describes ways one might get access to these treatments.
NCI-designated cancer centers0.38027
specific drug0.365425
following criteria0.380266
NCI program0.360621
NCI’s Cancer0.393319
case-by-case basis0.385443
specific investigational drug0.531382
FDA approval process0.46336
NCI’s role0.358363
TRC protocol0.386712
Biologics License Application0.383962
Institutional Review Board0.372082
special exception programs0.401115
investigational agent0.482556
clinical trials0.558265
specific criteria0.382975
U.S. Food0.350319
special exception mechanism0.383615
clinical trial0.636376
patients0.498827
Special Exception/Compassionate Exemption0.383931
access protocol0.441767
drug development0.379672
study sponsor0.351362
Investigational New Drug0.563996
FDA approval0.502957
New Drug Application0.4108
wide geographic availability0.374872
NCI0.425588
expanded access protocols0.412645
IND0.351277
investigational drug0.866441
sponsor0.450913
treatment0.39466
access0.446945
new drugs0.396554
Drug Administration0.379954
Cancer Information Service0.448715
special exception0.541023
compassionate exception0.351227
investigational drugs0.95169
patient0.385651
appropriate reviewing division0.371824
drug company0.56293
expanded access protocol0.400476
health insurance company0.376702
CIS information specialists0.382598
clinical trials database0.391459
Treatment Referral Center0.38112
CLICK HERE
1937 National Cancer Institute Html es Tratamiento de los cánceres poco comunes en la niñez (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de los cánceres poco comunes en la niñez como los cánceres de la cabeza y el cuello, el tórax, el abdomen, el aparato reproductor, la piel y otros.
glándula tiroides0.938162
siguientes procedimientos0.472657
posibles efectos tardíos0.3766
hormona tiroidea0.437118
color blanco plateado0.323284
adultos jóvenes0.322007
efectos secundarios meses0.525317
faja ajustadora0.360779
pequeña cantidad0.416767
tratamiento causa0.422854
células normales.ampliar exploración0.550413
ecografía completa0.326705
vía oral0.351058
rayos x0.35409
Masas indoloras0.337566
niño ayuda0.375685
efectos tardíos0.809559
escáner.ampliar exploración0.389789
PDQ Efectos tardíos0.373896
vías respiratorias0.465531
tarde.ampliar ecografía0.364218
órgano fonador0.316018
tumores benignos0.352678
gen apc0.327747
endocrina múltiple tipo0.438625
PDQ Tratamiento0.416786
área pequeña detrás0.333456
gen nut0.365005
siguientes problemas0.361501
explorador tep0.372891
siguientes signos0.678578
nuevos tipos0.336277
gen pten0.328711
enfermedad.ampliar endoscopia0.360667
linfocitos t0.350025
hormona calcitonina0.330174
células tiroideas0.433364
toma imágenes0.349043
Ojos saltones0.331931
CLICK HERE
2060 National Cancer Institute Html es Cuidados paliativos durante el cáncer Describe la función de los cuidados paliativos, los cuales son los cuidados que se brindan a pacientes que tienen una enfermedad grave o potencialmente letal, como el cáncer, desde el momento del diagnóstico y durante todo el curso de la enfermedad.
Cáncer patrocina investigación0.300839
Cáncer Servicios0.300985
Palliative Care Organization0.300646
siguientes problemas0.300582
cuidado médico0.300437
familiar enfermo0.300321
Palliative Care0.301049
amplia gama0.300339
profesional médico0.30124
Advance Palliative Care0.300677
National Hospice0.300346
largo plazo0.3012
profesionales médicos0.301302
Whole Patient0.300325
Cáncer Etapa final0.301212
cuidados paliativos0.999612
National Cancer Institute0.300463
resultado necesidades0.300363
seguro médico0.301606
CLICK HERE
3598 National Cancer Institute Html en Childhood Cancer Survivor Study: An Overview Health problems that develop years later as a result of a cancer treatment are known as late effects. The Childhood Cancer Survivor Study (CCSS) was started in 1994 to better understand these late effects.
Cancer Survivor Study0.651761
Clinical Oncology0.430017
childhood cancer0.933179
journal article0.545579
childhood cancer survivor0.797555
CLICK HERE
14596 National Cancer Institute Html en What Is Cancer? Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.
benign brain tumors0.40676
star-shaped brain cells0.473891
human cells0.482443
nearby normal cells0.498609
squamous cells0.495031
body’s cells0.493774
tumor suppressor genes0.441927
white blood cells0.5174
malignant tumors0.410135
Reed-Sternberg cells0.446673
abnormal plasma cells0.47073
tissues0.391204
epithelial cell types0.372838
extra cells0.532701
blood vessels0.389179
nerve cells0.450383
solid tumors0.421449
DNA repair genes0.397134
Metastatic tumors0.385874
carcinoid tumors0.394635
metastatic breast cancer0.390046
cancers0.429846
immune system cells0.472603
myeloma cells0.447313
soft tissue sarcoma0.382156
neuroendocrine tumors0.396625
different cells0.465518
abnormal cells0.497795
metastatic cancer cells0.542261
cancer cells0.711115
normal blood cells0.520987
unneeded cells0.469669
new cells0.509463
squamous cell0.373428
normal cells0.564574
types0.419663
epithelial cells0.524359
Cancerous tumors0.382835
genetic changes0.400724
tumors0.551639
germ cell tumors0.421823
cells0.91549
new tumors0.381387
benign tumors0.426682
damaged cells0.483579
cells function0.467145
cancer0.716841
leukemia cells0.447258
spinal cord tumors0.44102
CLICK HERE
15653 National Cancer Institute Html en Grant Closeout Learn about the administrative actions and requirements to comply with grants closeout.
recipient institution0.403385
current competitive segment0.4584
Final Research Performance0.470424
FRPPR0.272101
Progress Report0.292765
recipient organization0.397988
business official0.281485
Report Additional Materials0.646337
new competitive segment0.466064
Interim RPPR0.480283
Final RPPR0.617886
Guide Notice0.494667
applicable administrative actions0.459328
project period0.315182
Process Final RPPR0.451009
Closeout status screen0.633167
federal government0.280609
eRA Commons0.988859
Final Report Additional0.435922
additional information0.556844
Guide Notice NOT-OD-17-0370.449856
future funding0.297581
Interim Report Additional0.450898
IRPPR link0.291974
IRPPR0.302645
property accountability0.290412
later refunds0.280936
competitive segment0.500951
grant closeout process0.873148
closeout documentation0.730869
current annual RPPR0.439246
financial accountability0.290106
Unilateral Closeout action0.746529
Signing Official0.282197
grant support0.576328
additional information online0.441695
record retention0.281581
renewal application0.63575
new institution0.307358
program directors0.303803
grant closeout reports0.857404
submission0.258668
CLICK HERE
16647 National Cancer Institute Html en Track 1: Oncology Product Research and Review for M.D. Oncology Fellows NCI and FDA collaborate to train physicians in clinical trials methodology and medical product development. Learn more about this cancer training program.
cancer treatment0.479728
product development process0.567202
review process0.489003
oncology training programs0.558331
FDA scientific review0.54729
permanent residency0.47764
Medical Center Dr0.53143
application guidelines0.474013
continued clinical activities0.563939
research goals0.484402
clinical trials methodology0.592427
post-marketing surveillance0.480689
Regulatory Review Fellowships0.542695
Cancer Training0.476448
wide variety0.47699
basic science0.47529
clinical research0.572543
clinical pharmacology0.56636
clinical aspects0.565731
Review list0.477947
application materials0.475814
regulatory pathways0.4862
U.S. citizenship0.479791
practical experience0.477134
cancer product development0.582309
earliest start date0.532518
regulatory aspects0.552684
critical ethical issues0.546923
medical product development0.68682
product research0.503682
board eligibility0.486187
product development research0.56952
internal medicine0.479825
clinical trial design0.90418
oncology subspecialty0.512496
new product development0.559224
epidemiology0.43097
product development0.772741
senior member0.472136
radiation oncology0.485841
human research subjects0.561696
Clinical training0.523355
course work0.477251
drug regulation0.476113
basic bench science0.561571
Personal statement0.473214
Office Phone0.471769
NCI-FDA Research0.483426
new agents0.475146
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.